TY - JOUR
T1 - Clinical whole exome sequencing in severe hypertriglyceridemia
AU - Tada, Hayato
AU - Nomura, Akihiro
AU - Okada, Hirofumi
AU - Nakahashi, Takuya
AU - Nozue, Tsuyoshi
AU - Hayashi, Kenshi
AU - Nohara, Atsushi
AU - Yagi, Kunimasa
AU - Inazu, Akihiro
AU - Michishita, Ichiro
AU - Mabuchi, Hiroshi
AU - Yamagishi, Masakazu
AU - Kawashiri, Masa aki
N1 - Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2019/1
Y1 - 2019/1
N2 - Background: Little data exist regarding the clinical application of whole exome sequencing (WES) for the molecular diagnosis of severe hypertriglyceridemia (HTG). Methods: WES was performed for 28 probands exhibiting severe HTG (≥1000 mg/dl) without any transient causes. We evaluated recessive and dominant inheritance models in known monogenic HTG genes, followed by disease-network gene prioritization and copy number variation (CNV) analyses to identify causative variants and a novel genetic mechanism for severe HTG. Results: We identified possible causative variants for severe HTG, including three novel variants, in nine probands (32%). In the recessive inheritance model, we identified two homozygous subjects with lipoprotein lipase (LPL) deficiency and one subject harboring compound heterozygous variants in both LPL and APOA5 genes (hyperchylomicronemia). In the dominant inheritance model, we identified probands harboring deleterious heterozygous variants in LPL, glucokinase regulatory protein, and solute carrier family 25 member 40 genes, possibly associated with this extreme HTG phenotype. However, gene prioritization and CNV analyses did not validate the novel genes associated with severe HTG. Conclusions: In 28 probands with severe HTG, we identified potential causative variants within nine genes associated with rare Mendelian dyslipidemias. Clinical WES may be feasible for such extreme cases, potentially leading to appropriate therapies.
AB - Background: Little data exist regarding the clinical application of whole exome sequencing (WES) for the molecular diagnosis of severe hypertriglyceridemia (HTG). Methods: WES was performed for 28 probands exhibiting severe HTG (≥1000 mg/dl) without any transient causes. We evaluated recessive and dominant inheritance models in known monogenic HTG genes, followed by disease-network gene prioritization and copy number variation (CNV) analyses to identify causative variants and a novel genetic mechanism for severe HTG. Results: We identified possible causative variants for severe HTG, including three novel variants, in nine probands (32%). In the recessive inheritance model, we identified two homozygous subjects with lipoprotein lipase (LPL) deficiency and one subject harboring compound heterozygous variants in both LPL and APOA5 genes (hyperchylomicronemia). In the dominant inheritance model, we identified probands harboring deleterious heterozygous variants in LPL, glucokinase regulatory protein, and solute carrier family 25 member 40 genes, possibly associated with this extreme HTG phenotype. However, gene prioritization and CNV analyses did not validate the novel genes associated with severe HTG. Conclusions: In 28 probands with severe HTG, we identified potential causative variants within nine genes associated with rare Mendelian dyslipidemias. Clinical WES may be feasible for such extreme cases, potentially leading to appropriate therapies.
KW - Exome sequencing
KW - Familial hyperchylomicronemia
KW - Lipoprotein lipase deficiency
KW - Triglyceride
UR - http://www.scopus.com/inward/record.url?scp=85055749464&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2018.10.041
DO - 10.1016/j.cca.2018.10.041
M3 - 学術論文
C2 - 30389453
AN - SCOPUS:85055749464
SN - 0009-8981
VL - 488
SP - 31
EP - 39
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -